SandboxAQ teams up with Sanofi to discover biomarkers through the use of advanced quantitative artificial intelligence
In an exciting development, SandboxAQ, a leading AI company, has entered into a collaboration with Sanofi to utilise their Large Quantitative Models (LQMs) for biomarker identification during clinical development.
SandboxAQ's LQMs are part of their causal filtration models, which are designed to filter through knowledge graphs, providing a more accurate and scalable approach compared to natural language LLM models trained on public data available on the Internet. These models are trained on multiple data streams, including proprietary data generated internally by SandboxAQ algorithms.
Jack Hidary, the CEO of SandboxAQ, has been at the forefront of AI projects within the company. Nadia Harhen, the General Manager of AI Simulation at Sandbox AQ, expressed her excitement about the impact of LQMs in various life science areas, including drug repurposing and reverse screening.
The application of these models in biomarker identification is particularly significant in clinical development. By understanding human biology and aiding in identifying new biomarkers, these AI models have the potential to unlock patient benefits beyond the early stages of drug discovery.
This collaboration with Sanofi is not the first for SandboxAQ. Last year, the company entered into Quantitative AI collaborations with the University of California San Francisco (UCSF), Novonix, and Riboscience. In 2024, Flagship Pioneering, SPARK NS, and other organisations signed on to further SandboxAQ's innovation pipelines.
The collaboration aims to identify biomarkers during clinical development, expanding SandboxAQ's reach into later stage clinical development. These Large Quantitative Models have proven impactful in multiple areas across the life sciences, and SandboxAQ will use them for causal filtering of knowledge graphs.
The use of these models assists in demonstrating the mechanism of action, efficacy, and safety of investigational medicines and targets. Furthermore, this technique allows automatic extraction of new clinical hypotheses from literature, a significant advantage in the rapidly evolving field of biomedical research.
With this collaboration, both SandboxAQ and Sanofi are poised to make significant strides in the field of biomarker identification, potentially leading to the development of more effective and safer drugs for patients worldwide.
Read also:
- Oral Semaglutide at a dose of 25 mg (the pill form of Wegovy*) led to a weight loss of 16.6% in individuals with obesity, as revealed in a recent study.
- Contribution to Youth Protection through Alcohol Purchases
- Probiotics and Eczema: Do They Provide Effective Relief?
- Stem cells potentially enhancing joint wellness and flexibility during aging process?
